Company Overview and News

1
HCN / Welltower Inc. 8-K (Current Report)

2018-04-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
HCN / Welltower Inc. 424B5 (Prospectus)

2018-04-04 sec.gov
424B5 Table of Contents CALCULATION OF REGISTRATION FEE
Upvote Downvote

 
HCN / Welltower Inc. FWP

2018-04-03 sec.gov
FWP Issuer Free Writing Prospectus, dated April 3, 2018 Filed Pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement Dated April 3, 2018 and
Upvote Downvote

 
HCN / Welltower Inc. 424B5 (Prospectus)

2018-04-03 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-203802 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting
Upvote Downvote

 
Why Is Welltower Inc. (WELL) Down -1.84% Since its Last Earnings Report?

2018-03-26 zacks
It has been about a month since the last earnings report for Welltower Inc. (WELL - Free Report) . Shares have lost about 1.8% in that time frame.
Upvote Downvote

 
HCN / Welltower Inc. DEFA14A

2018-03-23 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A
Upvote Downvote

 
HCN / Welltower Inc. DEF 14A

2018-03-23 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A
Upvote Downvote

 
HCN / Welltower Inc. 8-K (Current Report)

2018-03-20 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
New Strong Sell Stocks for March 15th

2018-03-15 zacks
Westinghouse Air Brake Technologies Corporation (WAB - Free Report) is a provider of equipment, systems, and services for the freight rail and passenger transit vehicles. The Zacks Consensus Estimate for its current year earnings has been revised 4.5% downward over the last 30 days.
Upvote Downvote

 
March 2018 Stock Considerations

2018-03-05 seekingalpha
A few days into the month of March, it is time, once again, to outline my potential stock picks for the month. After many, many months of a market that was on a never-ending melt-up run, we have been suddenly reacquainted with the notion of volatility. By any measure, the stock market has been an exciting place to be in February as we witnessed wild moves in many of the averages as well as individual stocks.
Upvote Downvote

1
If I Had To Build An Income Portfolio Today - Update 27

2018-03-05 seekingalpha
This article is Update 27 to my original article entitled "If I Had to Build An Income Portfolio Today."
Upvote Downvote

 
Is 6.7%-Yielding Welltower Inc. A Buy Right Now?

2018-03-01 seekingalpha
Fundamentals in the health care REIT market are intact, and Welltower continues to cover its dividend payout with cash flow relatively easily.
Upvote Downvote

1
I Am A 'FearLeader' For Senior Housing Properties

2018-03-01 seekingalpha
In case you missed it, I wrote a detailed article on externally managed REIT, Government Properties Trust (GOV), yesterday in which I explained,
Upvote Downvote

1
HCN / Welltower Inc. 10-K (Annual Report)

2018-02-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 95040Q104